Literature DB >> 1980219

Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone.

R Weber1, B Ledergerber, M Opravil, W Siegenthaler, R Lüthy.   

Abstract

OBJECTIVE: To see whether misusers of injected drugs who stop injecting or switch to a programme of maintenance treatment with methadone have a reduced risk of progression of HIV infection when compared with a group of persistent misusers.
DESIGN: Observational cohort study in HIV seropositive subjects with a current or past history of misusing injected drugs.
SETTING: HIV outpatient clinic at the University Hospital of Zurich, Switzerland. PATIENTS: 297 Current and former parenteral drug misusers (median age 27) with asymptomatic HIV infection. During the observation period 80 subjects adhered to a programme of maintenance treatment with methadone, 124 continued with parenteral drug misuse, and 93 former misusers remained free of illicit drugs. No antiretroviral treatment was given during the study. MAIN OUTCOME MEASURES: Probability of progression of HIV infection from asymptomatic to symptomatic (Centers for Disease Control stage IV) as calculated by life table analysis and compared in the three groups of patients by means of a log rank test, and predictors of disease progression as analysed with a Cox proportional hazards regression model.
RESULTS: The 297 patients were followed up for a median of 16 months. The median duration of injecting drug misuse before enrollment was 7.1 years. There were no significant differences among the three groups with respect to CD4+ counts at the beginning of the study (median 0.44 x 10(9)/l). Life table analysis showed a significantly lower probability of progression of HIV disease in both the methadone treated group and former drug misusers than in persistent injecting drug misusers. Multivariate regression analysis showed a relative risk of progression of the disease of 1.78 (95% confidence interval 1.20 to 2.67; p less than 0.01) in persistent injecting drug misusers, 0.48 (0.29 to 0.77; p less than 0.01) in the methadone treated group, and 0.66 (0.41 to 1.06; p = 0.085) in former drug misusers.
CONCLUSIONS: Stopping the misuse of injected drugs slows the progression of HIV disease in infected subjects. Drug treatment programmes are effective in secondary prevention of HIV associated morbidity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980219      PMCID: PMC1664524          DOI: 10.1136/bmj.301.6765.1362

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

1.  Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus.

Authors:  M G Davis; S C Kenney; J Kamine; J S Pagano; E S Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

Review 3.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

4.  Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.

Authors:  D C Des Jarlais; S R Friedman; M Marmor; H Cohen; D Mildvan; S Yancovitz; U Mathur; W el-Sadr; T J Spira; J Garber
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

5.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Authors:  D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky
Journal:  JAMA       Date:  1989-02-17       Impact factor: 56.272

6.  Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men.

Authors:  F de Wolf; J M Lange; J T Houweling; R A Coutinho; P T Schellekens; J van der Noordaa; J Goudsmit
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

Review 7.  Methadone treatment and acquired immunodeficiency syndrome.

Authors:  J R Cooper
Journal:  JAMA       Date:  1989 Sep 22-29       Impact factor: 56.272

8.  Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus.

Authors:  P R Skolnik; B R Kosloff; M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

9.  No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study.

Authors:  R A Kaslow; W C Blackwelder; D G Ostrow; D Yerg; J Palenicek; A H Coulson; R O Valdiserri
Journal:  JAMA       Date:  1989-06-16       Impact factor: 56.272

Review 10.  Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users.

Authors:  P W Brickner; R A Torres; M Barnes; R G Newman; D C Des Jarlais; D P Whalen; D E Rogers
Journal:  Ann Intern Med       Date:  1989-05-15       Impact factor: 25.391

View more
  14 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Injection drug use, mortality, and the AIDS epidemic.

Authors:  P A Selwyn
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

Review 3.  Immunosuppressive effects of opioids--clinical relevance.

Authors:  Alexander Brack; Heike L Rittner; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

4.  The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.

Authors:  Farzana Kapadia; Judith A Cook; Marge H Cohen; Nancy Sohler; Andrea Kovacs; Ruth M Greenblatt; Imtiaz Choudhary; David Vlahov
Journal:  Addiction       Date:  2005-07       Impact factor: 6.526

Review 5.  Clinical aspects of HIV infection in women.

Authors:  G O Coodley; M K Coodley; A F Thompson
Journal:  J Gen Intern Med       Date:  1995-02       Impact factor: 5.128

6.  Accounting for dropout reason in longitudinal studies with nonignorable dropout.

Authors:  Camille M Moore; Samantha MaWhinney; Jeri E Forster; Nichole E Carlson; Amanda Allshouse; Xinshuo Wang; Jean-Pierre Routy; Brian Conway; Elizabeth Connick
Journal:  Stat Methods Med Res       Date:  2015-06-15       Impact factor: 3.021

7.  Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting.

Authors:  Brenden Joseph; Thomas Kerr; Cathy M Puskas; Julio Montaner; Evan Wood; M-J Milloy
Journal:  AIDS Care       Date:  2015-04-27

8.  HIV-specific changes in the motor performance of HIV-positive intravenous drug abusers.

Authors:  H J von Giesen; H Hefter; H Roick; S Mauss; G Arendt
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

Review 9.  Methadone maintenance treatment: an update.

Authors:  G Bertschy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

Review 10.  [Opioid-induced immunosuppression. A clinically relevant problem?].

Authors:  H L Rittner; A Brack
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.